Cancer is complex and dynamic—ergo, dose optimization calls for mathematical modeling

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

We wish to applaud the sentiments expressed in the recent article in The Cancer Letter titled “Oncologists, advocates, FDA call for an end to MTD and ‘more is better’ era in cancer drug dosing,” but also raise several concerns to be addressed as this initiative moves forward. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Department chair, Integrated Mathematical Oncology; Co-director, Center of Excellence for Evolution-based Therapy, Moffitt Cancer Center
Vice chair, Radiology Research; Chair, Department of Cancer Physiology, Moffitt Cancer Center
Department chair and program leader, Diagnostic Imaging and Interventional Radiology; Co-director, Center of Excellence for Evolution-based Therapy; Co-director, Cancer Biology and Evolution Program, Moffitt Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Department chair, Integrated Mathematical Oncology; Co-director, Center of Excellence for Evolution-based Therapy, Moffitt Cancer Center
Vice chair, Radiology Research; Chair, Department of Cancer Physiology, Moffitt Cancer Center
Department chair and program leader, Diagnostic Imaging and Interventional Radiology; Co-director, Center of Excellence for Evolution-based Therapy; Co-director, Cancer Biology and Evolution Program, Moffitt Cancer Center

Login